The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is presented.

Bibliographic Details
Main Authors:	O. V. Tsygankova, L. D. Latyntseva, T. I. Batluk, D. Yu. Platonov, N. M. Akhmedzhanov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2019-12-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	off-label use гемодинамическая стенокардия триметазидин
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/2341

Similar Items

Anti-anginal and anti-ischemic effectiveness of trimetazidine MB in patients with unstable angina
by: M. G. Glezer, et al.
Published: (2009-02-01)

Pharmacological treatment of stable angina pectoris: the place of trimetazidine
by: E. A. Temnikova
Published: (2022-12-01)

Comparing effectiveness of adding prolonged trimetazidine or isosorbide dinitrate to beta-adrenoblocker therapy in stable angina patients
by: M. G. Glezer, et al.
Published: (2006-08-01)

Carbohydrate metabolism parameters in angina patients treated with metoprolol and its combination with trimetazidine
by: E. V. Bochkareva, et al.
Published: (2012-08-01)

Legal and Medical Aspects of Off-Label Medication Use. Point of View
by: O. V. Tsygankova, et al.
Published: (2019-03-01)

Results of Holter monitoring in patients with angina pectoris treated by combination of trimethazidine with fabomotisol in the area of former armed conflict
by: Z. Yu. Shakhbieva, et al.
Published: (2019-06-01)

TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
by: M. V. Novikova, et al.
Published: (2014-10-01)

New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study PERSPECTIVE (Part II)
by: M. G. Bubnova, et al.
Published: (2011-12-01)

Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
by: L. V. Kremneva, et al.
Published: (2005-04-01)

TRIMETAZIDINE MR EFFECTS ON THE PARAMETERS OF 24-HOUR ELECTROCARDIOGRAM MONITORING AND HEART RATE VARIABILITY
by: M. V. Novikova, et al.
Published: (2013-10-01)

INTERCHANGEABILITY OF MYOCARDIAL CYTOPROTECTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE. DIFFICULT QUESTIONS –SIMPLE SOLUTIONS
by: Zh. M. Sizova
Published: (2015-09-01)

Primenenie Trimetazidina u pozhilykh patsientov s refrakternoy stenokardiey, stradayushchikh sakharnym diabetom
by: A A Smirnov, et al.
Published: (2003-06-01)

New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients
by: N. A. Nikolaev
Published: (2008-02-01)

Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)
by: N. M. Kolomoets, et al.
Published: (2009-12-01)

Trimetazidine effects on mitochondria energetic activity
by: S. V. Eliseeva, et al.
Published: (2008-12-01)

PROSPECTS FOR CYTOPROTECTORS USE IN THE ELDERLY PATIENTS THROUGH THE EXAMPLE OF CALCIFIED AORTIC STENOSIS AND ISCHEMIC HEART DISEASE
by: N. Yu. Karpova, et al.
Published: (2015-09-01)

Myocardial cytoprotectors demonstrate anti-apoptotic effect on vascular endotheliocytes
by: A. I. Inzhutova
Published: (1970-01-01)

Effectiveness of the original trimetazidine MR in patients with stable coronary heart disease and angina attacks resistant to trimetazidine generics (ETALON study)
by: A. V. Fendrikova, et al.
Published: (2011-08-01)

Trimetazidine MB treatment in patients with chronic heart failure
by: T. E. Morozova, et al.
Published: (2010-06-01)

The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole
by: V. V. Kalyuzhin, et al.
Published: (2002-03-01)

Trimetazidine in chronic heart failure patients aged above 75 years
by: I. V. Ignatenko, et al.
Published: (1970-01-01)

ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS
by: Lei Zhang, et al.
Published: (2015-12-01)

Trimetazidine MR effects on heart remodeling in stable coronary heart disease patients
by: E. M. Khurs, et al.
Published: (2007-02-01)

CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY
by: O. E. Antsiferova, et al.
Published: (2021-03-01)

Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome
by: M. G. Glezer, et al.
Published: (2009-08-01)

EFFECTS OF TRIMETAZIDINE ON THE TRANSMITRAL BLOOD FLOW IN PATIENTS WITH DIASTOLIC HEART FAILURE
by: Yu. N. Fedulaev, et al.
Published: (2015-09-01)

IMPACT OF NICORANDIL IN ANGINA: SUBGROUP ANALYSES
by: IONA Study Group
Published: (2010-08-01)

Physician's knowledge and experience with the off-label use of medicines
by: Maria Drenska, et al.
Published: (2021-01-01)

Trimetazidine effects on red blood cell membrane lipids and necrosis area size in thrombolytic therapy of myocardial infarction
by: T. Yu. Rebrova, et al.
Published: (2009-04-01)

Stable angina diagnostics and treatment in elderly patients
by: V. P. Lupanov, et al.
Published: (2008-10-01)

THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
by: L. E. Chekuldaeva, et al.
Published: (2015-12-01)

Database study of lenalidomide (Revlimid) in Germany: monitoring off-label use [Monitoring des Off-Label-Use von Lenalidomid (Revlimid) in Deutschland]
by: Dörks, Michael, et al.
Published: (2013-07-01)

Research on Approaches for Regulation of the “Off-label” use of Medicinal Products in the European Union
by: Drenska M., et al.
Published: (2017-05-01)

Clinical effectiveness of trimetazidine as a leading cardiovascular drug with metabolic action
by: A. Yu. Gasparyan, et al.
Published: (2008-08-01)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.
by: Weilan Wang, et al.
Published: (2013-05-01)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
by: Weilan Wang, et al.
Published: (2013-05-01)

Effectiveness of a selective If channel inhibitor ivabradine in patients with stable angina
by: E. V. Kuleshova
Published: (2009-10-01)

PATENT DUCTUS ARTERIOSUS - GOOD AND EVIL IN ONE VESSEL
by: E L Bokerya, et al.
Published: (2017-12-01)

Place of drugs acting on metabolism in primary health care in the prevention and treatment of ischemic syndromes
by: A. M. Shilov
Published: (2015-12-01)

Secondary prevention effectiveness in patients with stable angina
by: Rasim Kutlu, et al.
Published: (2010-08-01)